AUTOTAC Bio develops targeted protein degradation therapies using AUTOTAC technology to selectively eliminate disease-causing protein aggregates. Their approach aims to provide novel treatments for conditions such as Alzheimer's disease, various cancers, metabolic disorders, and muscular dystrophy by promoting autophagic degradation of harmful proteins.
Funding
Funding not disclosed
Founders
Product
Problem
Many diseases, including Alzheimer's, cancer, metabolic disorders, muscular dystrophy, and amyloidosis, are characterized by the accumulation of toxic protein aggregates. Current treatments often fail to selectively eliminate these disease-causing proteins, leading to limited efficacy and potential side effects.
Solution
AUTOTAC Bio develops targeted protein degradation therapies using its AUTOTAC (AUTophagy-Targeting Chimera) technology. This platform selectively eliminates disease-causing protein aggregates by promoting their autophagic degradation, a natural cellular process for removing unwanted materials. AUTOTACs are designed to specifically target and degrade proteins implicated in various diseases, offering a potential therapeutic approach for conditions with limited treatment options. The company's ATL compounds can also synthetically activate lipophagy to promote the breakdown of fatty lipids and regulate glucose levels for treating metabolic diseases.
Target Audience
The primary target audience includes researchers and pharmaceutical companies focused on developing novel therapies for Alzheimer's disease, cancer, metabolic disorders, muscular dystrophy, and amyloidosis.
Features
- AUTOTAC technology platform for targeted degradation of disease-causing proteins
- ATL compounds that activate lipophagy for lipid breakdown and glucose regulation
- Selective degradation of KRas and mutant p53 aggregates for cancer therapy
- Inhibition of excessive actin degradation to halt muscle wasting in muscular dystrophy
- Targeted degradation of amyloidogenic aggregates to counteract tissue deposits in amyloidosis
- Novel P62 ligand compounds for preventing, ameliorating, or treating proteinopathies